Benralizumab + Placebo
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Severe Prednisone Dependent Eosinophilic Asthma
Conditions
Severe Prednisone Dependent Eosinophilic Asthma
Trial Timeline
Apr 26, 2018 → Nov 30, 2022
NCT ID
NCT03470311About Benralizumab + Placebo
Benralizumab + Placebo is a phase 3 stage product being developed by AstraZeneca for Severe Prednisone Dependent Eosinophilic Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT03470311. Target conditions include Severe Prednisone Dependent Eosinophilic Asthma.
What happened to similar drugs?
20 of 20 similar drugs in Severe Prednisone Dependent Eosinophilic Asthma were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05692180 | Phase 3 | Recruiting |
| NCT05251909 | Phase 3 | Terminated |
| NCT04612790 | Phase 3 | Terminated |
| NCT04191304 | Phase 3 | Active |
| NCT04185012 | Phase 3 | Completed |
| NCT03953300 | Approved | Active |
| NCT04053634 | Phase 3 | Completed |
| NCT03470311 | Phase 3 | Completed |
| NCT03473977 | Phase 2/3 | Completed |
| NCT03186209 | Phase 3 | Completed |
| NCT02322775 | Phase 3 | Completed |
| NCT01947946 | Phase 3 | Terminated |
| NCT01928771 | Phase 3 | Completed |
| NCT01914757 | Phase 3 | Completed |
Competing Products
20 competing products in Severe Prednisone Dependent Eosinophilic Asthma